

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: _____ Signature: _____
(Downetta Teagle-Tate)

Docket No.: 007048010US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Stephen J. Kent

Application No.: 10/560,069

Confirmation No.: 6553

Filed: December 9, 2005

Art Unit: 1644

For: IMMUNOMODULATING
COMPOSITIONS, USES THEREFORE
AND PROCESSES FOR THEIR
PRODUCTIONS

Examiner: A. E. Juedes

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information that may be material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 50-2283 in the amount of \$180.00 covering the fees set forth in 37 CFR 1.17(p) and 1.17(a)(3).

Application No.: 10/560,069

Docket No.: 007048010US

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-2283, under Order No. 007048010US.

Date December 10, 2009

Respectfully submitted,

By 
Joseph W. Ricigliano

Registration No.: 48,511
Paul M. Booth

Registration No.: 40,244
PERKINS COIE LLP
607 Fourteenth Street, N.W.
Washington, DC 20005-2003
(202) 628-6600
(202) 434-1690 (Fax)
Attorneys for Applicant